European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s market share later this year between Amgen, Boehringer Ingelheim ...

Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires. The generics and biosimilars arm of ...

The FDA approved Amjevita as the first adalimumab biosimilar in 2016, but due to years of patent litigation, the U.S. was only able to get adalimumab biosimilars on the market starting in 2023.

Sandoz pointed to the uptake of its Humira biosimilar Hyrimoz in the US through a private-label agreement with CVS biosimilar subsidiary Cordavis as one of the drivers of its biosimilar business ...

The adalimumab segment is the largest revenue contributor to the market. Based on indication, the global biosimilar monoclonal antibodies market is segmented into oncology, autoimmune diseases ...

Celltrion, Inc., today announced that STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab) has been added to ...

Switching from a trusted medication like Humira to a biosimilar can be challenging for employees, making proactive communication and support critical. Employers should provide clear ...

"Year to date" sales for 2021, 2022, 2023, and 2024 sales are shown in series at the top of the table and then just below a comparison of 2024 versus 2023 and 2024 versus 2022 is displayed.

Alvotech prioritizes maximizing biosimilar HUMIRA’s penetration in U.S. and ... I have a question around interchangeability. Could you compare and contrast the interchangeability and how ...

As a part of this transaction, we are also acquiring a new preclinical development program, a biosimilar candidate to Cimzia that is in the same category of biologics as Humira and Stelara.